转自：中国证券报·中证网 中证报中证网讯（记者 李梦扬）2月24日，云顶新耀公告，公司于当日以线上虚拟会议形式举行的股东 特别大会顺利召开，会议所提呈的全部决议案均获股东正式通过。 记者获悉，本次股东特别大会批准、确认及追认了公司于2025年12月11日与海森生物医药有限公司（简 称"海森生物"）签署的商业化服务协议及其项下拟进行的相关交易，为公司后续商业化运营及业务推进 提供支持。与此同时，大会还批准了向公司管理层授出奖励安排，以及采纳2026年股份计划及相关授权 限额等决议案。 据了解，公司全资附属公司云顶新耀医药科技有限公司（简称"云顶新耀医药科技"）已与海森生物签署 两项战略合作协议，包括商业化服务协议以及授权许可协议。根据商业化服务协议，云顶新耀医药科技 将依托现有的销售与市场体系，为海森生物旗下六款成熟产品提供商业化服务。根据授权许可协议，云 顶新耀医药科技获得在大中华区开展莱达西贝普（Lerodalcibep）的后续临床开发、注册和商业化的独 家许可。商业化服务协议预计将于2026年上半年完成交割（以常规交割条件为准），授权许可协议将立 即生效。 云顶新耀此前表示，公司与海森生物的合作有助于进一 ...

Core Insights - Maiwei Biotech has received approval from the National Medical Products Administration (NMPA) for its IL-11 monoclonal antibody 9MW3811 to enter Phase II clinical trials for pathological scars, marking it as the first drug targeting this indication in clinical exploration [1] - The company has established an exclusive licensing agreement with CALICO Life Sciences, which includes an upfront payment of $25 million and potential milestone payments totaling up to $571 million, along with tiered royalties based on net sales [1][2] - Maiwei Biotech reported a significant revenue increase of 301.03% year-on-year, reaching 566 million yuan in the first three quarters of 2025, driven primarily by income from innovative product collaborations [2] Group 1: Clinical Development and Partnerships - The company has a comprehensive pipeline with 15 core products at various stages, including 11 innovative drugs and 4 biosimilars, focusing on oncology and age-related diseases [2] - The Phase II clinical trial for the anti-TMPRSS6 monoclonal antibody 9MW3011 has commenced, with the first patient dosed in the U.S., marking a significant milestone in its collaboration with DISC Medicine [3] - Maiwei Biotech has entered into a partnership with Qilu Pharmaceutical for long-acting white blood cell-boosting drugs, with a contract value of up to 500 million yuan, including a non-refundable upfront payment of 380 million yuan [4] Group 2: Financial Performance - The substantial increase in technical service revenue is attributed to the licensing agreements with CALICO, Qilu, and DISC, indicating the successful commercialization of innovative research [4] - The company’s revenue from technical services reached 407 million yuan, a year-on-year increase of 715.52%, while drug sales contributed 156 million yuan, reflecting a 72.10% increase [2] - Maiwei Biotech's ongoing clinical trials for its core pipeline products, including 9MW2821 and JS207, show promising efficacy signals in treating triple-negative breast cancer [5]

Summary of the Conference Call for 诺诚健华 Company Overview - **Company**: 诺诚健华 (Nocera Biopharma) - **Industry**: Biotechnology and Pharmaceuticals Key Financial Highlights - Total revenue for the first three quarters reached **¥11.2 billion**, a **59.8%** year-on-year increase [2][3][8] - Core product **奥布替尼 (Aubutin)** contributed **¥10.1 billion**, growing **45.8%** year-on-year [2][3][8] - The company expects full-year revenue to exceed **¥20 billion**, with a cash reserve of approximately **¥78 billion** (around **$10 billion**) [3][8] Product Development and Approvals - **奥布替尼** received approval for first-line treatment of chronic lymphocytic leukemia in China, expanding its commercial potential [5][11] - **Tansitumab** for diffuse large B-cell lymphoma has been approved and is now prescribed in over **20 provinces** in China [4][10][14] - New drug application for **Zula Tract Nap Nap** has been accepted and prioritized for review [2][5] - Ongoing clinical research includes **9 Phase III trials**, with plans for multiple new molecules to enter clinical stages annually [4][7][40] Strategic Partnerships - A global collaboration agreement with **Xenios BioPharma** was established, granting rights for **奥布替尼** outside Greater China and Southeast Asia, with a total deal value exceeding **$2 billion** [2][6][12][13] - Previous collaboration with **Prelude** for CD3/CD20 bispecific antibodies in autoimmune diseases [6] Market Performance and Future Outlook - The company anticipates achieving **break-even** by **2026** and sustainable profitability post-2027 through new drug promotions [4][7][38] - **奥布替尼** is expected to maintain its leading position in the marginal zone lymphoma market, with further growth anticipated from new indications [9][30] - The company is focused on expanding its hospital coverage and enhancing patient education to boost product awareness [30][31] Clinical Research and Innovations - **奥布替尼** is advancing in autoimmune disease research, with a Phase III NDA submission for **ITP** expected in the first half of **2026** [11][26] - The development of **Mesothelin**, a new BCL-2 inhibitor, shows promising results in various cancers, with a total market potential exceeding **$20 billion** [15][16] - **泰喜多单抗** is noted for its superior efficacy in DOR and OS compared to other mechanism drugs, enhancing its market position [14] Financial Projections and Cost Management - R&D expenses for **2025** are projected to be under **¥1 billion**, with sales expenses expected to account for **40%** of commercial product sales [36] - The company aims to maintain a commercial expense ratio of **35% to 40%** in **2026**, while increasing efficiency [37] Strategic Goals - The future strategy includes continuous innovation pipeline development, enhancing commercialization capabilities, and expanding market coverage [39] - The company plans to submit **5 to 7 new molecules** for clinical trials in the coming year, which will be crucial for its growth trajectory [40] This summary encapsulates the key points from the conference call, highlighting the company's financial performance, product developments, strategic partnerships, and future outlook in the biotechnology industry.